UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)¹

Pain Therapeutics, Inc.
(Name of Issuer)
Common Stock, \$0.001 par value
(Title of Class of Securities)
69562K 10 0
(CUSIP Number)
December 31, 2013
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1	NAME OF REPORTING PERSON					
		Biotechnology Value Fund, L.P.				
2	CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP	(a) x (b) o			
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
NUMBER OF	5	SOLE VOTING POWER				
SHARES BENEFICIALLY		0 shares				
OWNED BY EACH	6	SHARED VOTING POWER				
REPORTING PERSON WITH		0.1				
PERSON WITH	o states					
	7 SOLE DISPOSITIVE POWER					
	0 shares					
	8	SHARED DISPOSITIVE POWER				
		0 shares				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	0 shares					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	0%					
12	TYPE OF REPORTIN	NG PERSON				
	PN					

1	NAME OF REPORTING PERSON					
	Biotechnology Value Fund II, L.P.					
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o				
3	SEC USE ONLY		(1)			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION				
	Delaware					
NUMBER OF	5	SOLE VOTING POWER				
SHARES BENEFICIALLY		0 shares				
OWNED BY EACH	6	SHARED VOTING POWER				
REPORTING PERSON WITH						
PERSON WITH	TH 0 shares 7 SOLE DISPOSITIVE POWER					
	SOLE DISPOSITIVE POWER					
	0 shares					
	8	SHARED DISPOSITIVE POWER				
		0 shares				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	0 shares					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	0%					
12	TYPE OF REPORTI	NG PERSON				
	PN					
ı	1 11					

1	NAME OF REPORTING PERSON						
	Investment 10, L.L.C.						
2	CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP	(a) x (b) o				
3	SEC USE ONLY		(8) 8				
4	CITIZENSHIP OR PI	LACE OF ORGANIZATION					
	Illinois						
NUMBER OF SHARES	5	SOLE VOTING POWER					
BENEFICIALLY		0 shares					
OWNED BY EACH REPORTING	6	SHARED VOTING POWER					
PERSON WITH		0 shares					
	7	7 SOLE DISPOSITIVE POWER					
		0 shares					
	8	SHARED DISPOSITIVE POWER					
		0 shares					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	0 shares						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	0%						
12	TYPE OF REPORTIN	NG PERSON					
	00						

1	NAME OF REPORTING PERSON			
	BVF Partners L.			
2	_ ,	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o		
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
NUMBER OF SHARES	5	SOLE VOTING POWER		
BENEFICIALLY		0 shares		
OWNED BY EACH REPORTING	6	SHARED VOTING POWER		
PERSON WITH		0 shares		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		0 shares		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	0 shares			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	0%			
12	TYPE OF REPORT	TING PERSON		
	PN, IA			

1	NAME OF REPORTING PERSON						
	BVF Inc.						
2	CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP	(a) x				
2	CEC LICE ONLY		(b) o				
3	SEC USE ONLY						
4	CITIZENSHIP OR P	LACE OF ORGANIZATION					
	Delaware						
NUMBER OF	5	SOLE VOTING POWER					
SHARES							
BENEFICIALLY OWNED BY EACH	C	0 shares					
REPORTING	6	SHARED VOTING POWER					
PERSON WITH		0 shares					
	7 SOLE DISPOSITIVE POWER						
	0 shares						
	8	SHARED DISPOSITIVE POWER					
		0 shares					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
10	0 shares						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	LERGERY OF GERRE	2 12 12 2 1 1 1 1 0 1 1 (b)					
	0%						
12	TYPE OF REPORTI	NG PERSON					
	60						
	CO						

1	NAME OF REPORTING PERSON						
		Mark N. Lampert					
2	CHECK THE APPRO	DPRIATE BOX IF A MEMBER OF A GROUP	(a) x (b) o				
3	SEC USE ONLY		·				
4	CITIZENSHIP OR P	LACE OF ORGANIZATION					
	United States						
NUMBER OF	5	SOLE VOTING POWER					
SHARES BENEFICIALLY		0 shares					
OWNED BY EACH	6	SHARED VOTING POWER					
REPORTING PERSON WITH							
TERSON WITH	N WITH 0 shares 7 SOLE DISPOSITIVE POWER						
	, SOLL DISTOSITIVE FOWER						
	0 shares						
	8	SHARED DISPOSITIVE POWER					
		0 shares					
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	0 shares						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	0%						
12	TYPE OF REPORTIN	NG PERSON					
	IN						

Item 1(a). Name of Issuer:

Pain Therapeutics, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

7801 N. Capital of Texas Highway

Suite 260

Austin, Texas 78731

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611

Citizenship: Delaware

Investment 10, L.L.C. ("ILL10") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Illinois

BVF Partners L.P. ("Partners") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

BVF Inc.

900 North Michigan Avenue, Suite 1100

Chicago, Illinois 60611 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 900 North Michigan Avenue, Suite 1100

Chicago, Illinois 60611 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, \$0.001 par value (the "Common Stock")

CUSIP Number:

Item 2(e).

	69562K 10 0					
Item 3.	If This	This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:				
	/x/ Not applicable.					
	(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.			
	(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.			
	(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.			
	(d)	//	Investment company registered under Section 8 of the Investment Company Act.			
	(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).			
	(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).			
	(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).			
	(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.			
	(i) // A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of Company Act.					
	(j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).					
	(k)	//	Group, in accordance with Rule $240.13d-1(b)(1)(ii)(K)$. If filing as a non-U.S. institution in accordance with Rule $240.13d-1(b)(1)(ii)(J)$, please specify the type of institution:			
Item 4.	Ownership					
	As of December 31, 2013, the Reporting Persons no longer beneficially owned any securities of the Issuer.					
Item 5.	Ownership of Five Percent or Less of a Class.					
	If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].					
Item 6.	Owners	Ownership of More than Five Percent on Behalf of Another Person.				
	Not Applicable.					
			9			

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the initial Schedule 13G filed with the SEC on April 20, 2012.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2014

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT